Patents by Inventor Sandra Rauser

Sandra Rauser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Determining an expression status of human epidermal growth factor receptor 2 (HER2) in a biological sample
    Patent number: 9164098
    Abstract: A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: October 20, 2015
    Assignee: Bruker Daltonik GmbH
    Inventors: Christian Albers, Eckhard Belau, Sören-Oliver Deininger, Sandra Rauser, Detlev Suckau, Axel Walch
  • DETERMINING AN EXPRESSION STATUS OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN A BIOLOGICAL SAMPLE
    Publication number: 20110059554
    Abstract: A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 10, 2011
    Inventors: Christian Albers, Eckhard Belau, Sören-Oliver Deininger, Sandra Rauser, Detlev Suckau, Axel Walch